ADMA Q1 revenue flat at $114.5M, ASCENIV up 28%; withdraws long-term guidance

ADMA BIOLOGICS, INC.

2026-Q1 EPS reported $0.19 revenue$114,493,000

Revenue $114.5M flat YoY; ASCENIV rev $97.5M (+28%) offset by BIVIGAM -54%.
GAAP net income $45.3M (+68%); Adjusted net income $40.7M (+22%); Adjusted EBITDA $59.7M (+24%).
FY 2026 guidance: rev $530-560M, Adj EBITDA $265-300M; withdraws long-term guidance due to market dynamics.
Audit committee review found no improper channel stuffing or undisclosed related-party transactions.
Cash from ops $58M; gross margin expanded to 71% from 53% on product mix shift.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ADMA BIOLOGICS, INC. reported three months ended March 31, 2026 results: revenue $114.5 Million, net income Adjusted Net Income (1) of $40.7 Million.

Period: three months ended March 31, 2026
Revenue: $114.5 Million
Net income: Adjusted Net Income (1) of $40.7 Million
Result: reported results

Exact text from the filing

--- EX-99.1 2 ef20072554_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update 1Q 2026 Total Revenue of $114.5 Million, Flat Year-Over-Year 1Q 2026 ASCENIV Revenue +28% Year-Over-Year; BIVIGAM Revenue -54% Year-Over-Year 1Q 2026 Adjusted Net Income (1) of $40.7 Million, 22% Year-Over-Year Growth

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

ADMA BIOLOGICS, INC. reported FY 2026 results: revenue $530 million to $560 million, net income $170 million to $200 million. Guidance initiated.

Period: FY 2026
Revenue: $530 million to $560 million
Net income: $170 million to $200 million
Guidance: initiated
Result: guidance update

Exact text from the filing

FY 2026 total revenue expected to be $530 million to $560 million • FY 2026 Adjusted Net Income expected to be $170 million to $200 million • FY 2026 Adjusted EBITDA expected to be $265 million to $300 million

View on SEC.gov

Browse all earnings releases →

ADMA BIOLOGICS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-26-019295

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.